Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 11/03/21
Should You Buy Regeneron Pharmaceuticals (REGN) Ahead of Earnings?Zacks Investment Research • 11/03/21
Will Eylea, Dupixent, REGEN COV Aid Regeneron (REGN) Q3 Earnings?Zacks Investment Research • 11/01/21
Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex diseaseGlobeNewsWire • 10/25/21
Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this diseaseGlobeNewsWire • 10/22/21
Regeneron (REGN) Outpaces Stock Market Gains: What You Should KnowZacks Investment Research • 10/20/21
FDA Expands Approval of Dupixent® (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe AsthmaPRNewsWire • 10/20/21
Has Regeneron Pharmaceuticals (REGN) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 10/18/21
Regeneron is seeking full FDA approval for its monoclonal antibody for two types of COVID-19 patientsMarket Watch • 10/14/21
FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19PRNewsWire • 10/14/21
Regeneron to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2021PRNewsWire • 10/11/21